Chiasma's Mycapssa Improves Acromegaly Related Symptoms After Switching From iSRLs

Chiasma Inc CHMA has announced new data from the MPOWERED Phase 3 trial of Mycapssa as the first oral therapy to treat acromegaly.

• Chiasma presented the data at the Endocrine Society's annual meeting.
• The data from MPOWERED showed that Mycapssa improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly.
• Additionally, Mycapssa met the pre-specified non-inferiority margin compared to long-acting iSRLs in the maintenance of biochemical response.
• Data showed that Mycapssa demonstrated non-inferiority to iSRLs in maintaining a biochemical response; 91% of the Mycapssa patients maintained insulin-like growth factor 1 (IGF-1) response.
• The overall mean symptom score decreased from 4.5 to 3.5; the mean change from baseline was statistically significant and clinically meaningful.
• Overall, 80.4% of the randomized patients maintained or improved their symptoms score during the run-in phase compared to baseline.
• At the end of the RCT phase, 15% of patients reported breakthrough acromegaly symptoms in the octreotide capsules group and 31% of patients in the iSRLs group.
• Adverse event incidence and nature were similar to the known octreotide safety profile and acromegaly disease burden.
• Price Action: CHMA shares are trading 3.8% higher at $3.54 in the premarket on the last check Monday.